Literature DB >> 33181185

Disintegrant Selection in Hydrophobic Tablet Formulations.

Sonja Bauhuber1, Gernot Warnke1, Alberto Berardi2.   

Abstract

The hydrophobicity of poorly soluble drugs can delay tablets disintegration. We probed here the influence of different disintegrants on the disintegration of challenging hydrophobic formulations. Tablets containing diluents, hydrogenated vegetable oil and either sodium starch glycolate (SSG), croscarmellose sodium (CCS) or crospovidone (XPVP) were prepared. The disintegration time of tablets was tested immediately and after storage at 40 °C and 75% RH in sealed bags. Results show that storage and compression force had a negative effect on disintegration, particularly with 1% disintegrant. The performance of the three disintegrants was in the following order: CCS (best) > SSG > XPVP. For example, tablets containing 1% CCS, SSG and XPVP, compressed at 20 kN, disintegrated in ≈3, ≈12 and ≈69 min, respectively, after two months storage. Settling volume, liquid uptake and effect of storage on physical properties of the pure disintegrants were also studied and revealed that the reduced performance of XPVP is related to: 1) its rapid, yet short-range expansion upon liquid exposure and 2) its change of behaviour on storage. In conclusion, CCS ensured rapid disintegration at low concentration across various compression forces and storage times. Thus, the use of CCS in hydrophobic tablet formulations is recommended.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 33181185     DOI: 10.1016/j.xphs.2020.11.002

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  1 in total

1.  Investigating the role of excipients on the physical stability of directly compressed tablets.

Authors:  Natalie Maclean; Ibrahim Khadra; James Mann; Helen Williams; Alexander Abbott; Heather Mead; Daniel Markl
Journal:  Int J Pharm X       Date:  2021-12-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.